Compare DexCom, Inc. (DXCM) vs Rent the Runway Inc (RENT) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

RENT stock trades at $3.24, down 2.99% on the day, with a bearish technical signal. The company reported Q1 2026 revenue growth of 29% year-over-year to $89.9 million, beating EPS expectations, but maintains negative net income and free cash flow. Leadership is in transition with a new interim CEO. The balance sheet shows negative shareholder equity of -$182.5 million and high debt levels, though the debt-to-asset ratio is projected to improve significantly by 2026.

The outlook is mixed: low valuation multiples (P/S 0.18) suggest potential upside, but persistent losses, high debt, and leadership changes pose significant risks. Analyst consensus is cautious with 42% buy ratings. Revenue growth and balance sheet improvements are key to watch, but the stock carries high risk due to profitability challenges.